DE69909636D1 - Verwendung von methoxymorpholino doxorubicin zur behandlung eines lebertumor - Google Patents

Verwendung von methoxymorpholino doxorubicin zur behandlung eines lebertumor

Info

Publication number
DE69909636D1
DE69909636D1 DE69909636T DE69909636T DE69909636D1 DE 69909636 D1 DE69909636 D1 DE 69909636D1 DE 69909636 T DE69909636 T DE 69909636T DE 69909636 T DE69909636 T DE 69909636T DE 69909636 D1 DE69909636 D1 DE 69909636D1
Authority
DE
Germany
Prior art keywords
liver tumor
treating
methoxymorpholino doxorubicin
methoxymorpholino
doxorubicin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69909636T
Other languages
English (en)
Other versions
DE69909636T2 (de
Inventor
Adele Pacciarini
Olga Valota
David Kerr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nerviano Medical Sciences SRL
Original Assignee
Pharmacia Italia SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia SpA filed Critical Pharmacia Italia SpA
Application granted granted Critical
Publication of DE69909636D1 publication Critical patent/DE69909636D1/de
Publication of DE69909636T2 publication Critical patent/DE69909636T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69909636T 1998-09-14 1999-08-27 Verwendung von methoxymorpholino doxorubicin zur behandlung eines lebertumor Expired - Lifetime DE69909636T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9820012.4A GB9820012D0 (en) 1998-09-14 1998-09-14 Use of an anthracycline derivative for the treatment of a liver tumor
GB9820012 1998-09-14
PCT/EP1999/006298 WO2000015203A2 (en) 1998-09-14 1999-08-27 Use of methoxymorpholino doxorubicin for the treatment of a liver tumor

Publications (2)

Publication Number Publication Date
DE69909636D1 true DE69909636D1 (de) 2003-08-21
DE69909636T2 DE69909636T2 (de) 2004-06-09

Family

ID=10838847

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69909636T Expired - Lifetime DE69909636T2 (de) 1998-09-14 1999-08-27 Verwendung von methoxymorpholino doxorubicin zur behandlung eines lebertumor

Country Status (26)

Country Link
EP (1) EP1112066B1 (de)
JP (2) JP5529360B2 (de)
KR (1) KR100685155B1 (de)
CN (1) CN1168452C (de)
AT (1) ATE245029T1 (de)
AU (1) AU773451B2 (de)
BR (1) BR9913627A (de)
CA (1) CA2343120C (de)
CZ (1) CZ295901B6 (de)
DE (1) DE69909636T2 (de)
DK (1) DK1112066T3 (de)
EA (1) EA004570B1 (de)
ES (1) ES2203175T3 (de)
GB (1) GB9820012D0 (de)
HK (1) HK1050853A1 (de)
HU (1) HU229186B1 (de)
ID (1) ID28035A (de)
IL (2) IL141645A0 (de)
MY (1) MY124247A (de)
NO (1) NO329746B1 (de)
NZ (1) NZ510445A (de)
PL (1) PL198025B1 (de)
PT (1) PT1112066E (de)
TW (1) TWI222868B (de)
UA (1) UA69423C2 (de)
WO (1) WO2000015203A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
WO2004038404A2 (en) * 2002-10-28 2004-05-06 Pharmacia Italia Spa Method for optimizing therapeutic efficacy of nemorubicin
US20060264388A1 (en) * 2003-02-26 2006-11-23 Olga Valota Method for treating liver cancer by intrahepatic administration of nemorubicin
US8940334B2 (en) 2007-05-11 2015-01-27 Nerviano Medical Sciences S.R.L. Pharmaceutical composition of an anthracycline
JP2016124818A (ja) * 2014-12-26 2016-07-11 日本化薬株式会社 転移性肝癌治療薬及び転移性肝癌の治療方法
PL244818B1 (pl) * 2021-11-03 2024-03-11 Urteste Spolka Z Ograniczona Odpowiedzialnoscia Związek-marker diagnostyczny raka wątroby, sposób wykrywania aktywności enzymatycznej, sposób diagnozowania raka wątroby, zestaw zawierający taki związek oraz związek do zastosowania medycznego

Also Published As

Publication number Publication date
EA200100353A1 (ru) 2001-10-22
GB9820012D0 (en) 1998-11-04
MY124247A (en) 2006-06-30
EP1112066A2 (de) 2001-07-04
WO2000015203A3 (en) 2000-07-20
TWI222868B (en) 2004-11-01
NO329746B1 (no) 2010-12-13
DE69909636T2 (de) 2004-06-09
NO20011116D0 (no) 2001-03-05
HUP0103557A2 (hu) 2002-01-28
KR100685155B1 (ko) 2007-02-22
NZ510445A (en) 2003-01-31
PL198025B1 (pl) 2008-05-30
KR20010075074A (ko) 2001-08-09
IL141645A0 (en) 2002-03-10
CN1168452C (zh) 2004-09-29
NO20011116L (no) 2001-05-14
AU773451B2 (en) 2004-05-27
PT1112066E (pt) 2003-11-28
CA2343120C (en) 2009-11-24
ATE245029T1 (de) 2003-08-15
UA69423C2 (uk) 2004-09-15
CZ295901B6 (cs) 2005-11-16
IL141645A (en) 2007-05-15
CA2343120A1 (en) 2000-03-23
JP2002524496A (ja) 2002-08-06
ES2203175T3 (es) 2004-04-01
JP2014088398A (ja) 2014-05-15
EP1112066B1 (de) 2003-07-16
BR9913627A (pt) 2001-05-22
WO2000015203A2 (en) 2000-03-23
DK1112066T3 (da) 2003-11-03
EA004570B1 (ru) 2004-06-24
HK1050853A1 (en) 2003-07-11
ID28035A (id) 2001-05-03
JP5529360B2 (ja) 2014-06-25
CZ2001895A3 (cs) 2001-08-15
HUP0103557A3 (en) 2002-12-28
PL348749A1 (en) 2002-06-03
CN1383382A (zh) 2002-12-04
HU229186B1 (en) 2013-09-30
AU5742199A (en) 2000-04-03

Similar Documents

Publication Publication Date Title
EA200100111A1 (ru) Ингибиторы фарнезилпротеинтрансферазы, обладающие in vivo радиосенсибилизирующими свойствами
EA200100573A1 (ru) Применение ингибитора циклооксигеназы-2, ингибитора матричной металлопротеиназы, противоопухолевого лекарственного средства и факультативно облучения в качестве комбинированного способа лечения неоплазии
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
BRPI0408476A (pt) métodos para melhorar a qualidade da pele
EP1961418A4 (de) Verwendung von isothiocyanat-verbindungen zur behandlung von prostata-erkrankungen und hautkrebs
NO20054988D0 (no) Preparater og metoder for behandling av cancer
DK1472541T3 (da) Afbildningsmidler og metoder til at afbilde NAALADase og PSMA
WO2004050026A3 (en) Compositions and methods for treating prostate cancer
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
CY1110329T1 (el) Πεγκυλιωμενη λιποσωμιακη δοξορουβικινη σε συνδυασμο με εκτεϊνασκιδινη 743
DE60324431D1 (de) Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata- oder gebahrmutterkrebs
IL125776A (en) Use of a cimicifuga racemosa extract for the manufacture of a drug for treating estrogen-dependent tumors
DE69909636D1 (de) Verwendung von methoxymorpholino doxorubicin zur behandlung eines lebertumor
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
DK1189627T3 (da) Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
PA8453601A1 (es) Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg coa reductasa para tratamiento del cancer
DE50111407D1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
DE69814691D1 (de) Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
BRPI0510062A (pt) derivados de antraciclina
EP1234585A3 (de) Zusammensetzungen zur Vorbeugung oder Behandlung von Krebs
BR0308976A (pt) Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NERVIANO MEDICAL SCIENCES S.R.L., NERVIANO, MI, IT